NCT04812691 - CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 10, 2020

Primary Completion Date

June 30, 2021

Study Completion Date

April 25, 2023

Conditions

Diffuse Large B Cell Lymphoma

Interventions

BIOLOGICAL

JWCAR029 (CD19-targeted Chimeric Antigen Receptor Cells)

Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWCAR029. During JWCAR029 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive 1 x 10\^8 CAR+T cells (JWCAR029) treatment by intravenous (IV) injection.

Trial Locations (2)

200025

Ruijin hospital, Shanghai

Unknown

Zhejiang university school of medicine first affiliated hospital, Hangzhou

All Listed Sponsors

lead

Shanghai Ming Ju Biotechnology Co., Ltd.

INDUSTRY